Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

levodopa

CORBILTA (PREVIOUSLY LEVODOPA/CARBIDOPA/ENTACAPONE SANDOZ)

levodopa (CORBILTA (PREVIOUSLY LEVODOPA/CARBIDOPA/ENTACAPONE SANDOZ)) is a dopamine d3 receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved EMA: approved Nervous system (N04) N04BA02
US status approved
Patents linked 15
Pipeline programs 11
News articles 1
Drug details — levodopa
US status
approved
Class
Nervous system (N04)
Route
ORAL
Patents
15
Programs
11
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

levodopa (CORBILTA (PREVIOUSLY LEVODOPA/CARBIDOPA/ENTACAPONE SANDOZ)) is a dopamine d3 receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN levodopa
Brand CORBILTA (PREVIOUSLY LEVODOPA/CARBIDOPA/ENTACAPONE SANDOZ)
Mechanism Dopamine D3 receptor agonist
Target D(3) dopamine receptor
Therapeutic class Nervous system (N04)
Route ORAL
Formulation POWDER
ATC code N04BA02
Originator Amneal Pharma Europe Ltd

Mechanism of action

Dopamine D3 receptor agonist

Primary target: D(3) dopamine receptor

Approval history

Authority Status Date
FDA approved —
EMA approved —

Recent coverage

View all news
Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA®
Medium impact NewsMay 30, 2026

Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA®

2 min

Merz Therapeutics has entered an exclusive agreement with Kvvit for INBRIJA® (levodopa inhalation powder). This partnership marks a significant regulatory update in the pharmaceutical landscape.

Dr. Elena Rossi

Pipeline programs

Search pipeline Sponsor programs
  1. Levodopa Phase 3 · Lxo Ireland Designated · Ischaemic Stroke
  2. Levodopa-Carbidopa Intestinal Gel (LCIG) Phase 3 · AbbVie · Advanced Parkinson's Disease
  3. ZB203L01 Phase 3 · ZAMBON S.P.A · Motor fluctuations in advanced Parkinson’s disease
  4. SPINALON (buspirone + levodopa + cardidopa) Phase 2 · United Therapeutics Europe · Spinal Cord Injury
  5. levodopa Phase 2 · BRIGHT MINDS BIOSCIENCES · Cocaine Dependence
  6. levodopa Phase 2 · United Therapeutics Europe · Parkinson Disease
  7. Levodopa Phase 1 · Blackmores Institute · Parkinson's Disease
  8. Levodopa 250mg and Carbidopa 25mg Test Drug tablet Phase 1 · Tillomed Laboratories · Bioequivalence

Related & competitor drugs

Browse all drugs
  1. aripiprazole Nervous system (N05)
  2. brexpiprazole Nervous system (N05)
  3. brivaracetam Nervous system (N03)
  4. bupivacaine Nervous system (N01)
  5. buprenorphine Nervous system (N07)
  6. caffeine citrate Nervous system (N06)

Related patents

Browse patents Amneal Pharma Europe Ltd patent hub

  1. US 12370163

    Levodopa dosing regimen

    Expires Mon Jul 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12303482

    Levodopa dosing regimen

    Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12303481

    Levodopa dosing regimen

    Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12295931

    Levodopa dosing regimen

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12263148

    Levodopa dosing regimen

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12263149

    Levodopa dosing regimen

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12201596

    Levodopa dosing regimen

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12194150

    Levodopa dosing regimen

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12109185

    Levodopa dosing regimen

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11986449

    Levodopa dosing regimen

    Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11246871

    Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9987242

    Treatment of Levodopa-induced Dyskinesias

    Expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9248113

    Infusion and injection solution of Levodopa

    Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8735382

    Infusion and injection solution of levodopa

    Expires Mon May 22 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7368435

    Topical endoparasiticide and ectoparasiticide formulations

    Expires Mon May 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is levodopa?

levodopa (CORBILTA (PREVIOUSLY LEVODOPA/CARBIDOPA/ENTACAPONE SANDOZ)) is a dopamine d3 receptor agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for levodopa?

CORBILTA (PREVIOUSLY LEVODOPA/CARBIDOPA/ENTACAPONE SANDOZ) is a marketed brand name for levodopa. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of levodopa?

levodopa has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.